文献速递胸部肿瘤

度伐利尤单抗联合一线化疗治疗初治恶性胸膜间皮瘤的DREAM试验

Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
PubMed 文献 · Lancet Oncol · 2020-01-01

DREAM是一项在澳大利亚9家医院开展的多中心、单臂、开放标签2期试验,评估度伐利尤单抗联合顺铂和培美曲塞一线治疗不可手术的恶性胸膜间皮瘤。54例可评估患者中,6个月无进展生存率为57%(95%CI 44-70),常见3-4级不良事件为中性粒细胞减少(13%)、恶心(11%)和贫血(7%)。结论认为该联合方案活性可观且安全性可接受,值得随机3期试验进一步验证。

要点

  • 度伐利尤单抗联合顺铂/培美曲塞一线治疗恶性胸膜间皮瘤6个月PFS率达57%。
  • 常见3-4级不良事件为中性粒细胞减少13%、恶心11%、贫血7%。
  • 5例治疗期间死亡均未归因于研究治疗,安全性总体可接受。

核心结论

  • 度伐利尤单抗联合顺铂和培美曲塞在晚期恶性胸膜间皮瘤一线治疗中显示出有前景的抗肿瘤活性及可接受的安全性。

研究设计与样本

  • DREAM为在澳大利亚9家医院开展的多中心、单臂、开放标签2期试验,含6例安全性导入期。
  • 纳入55例初治、组织学确诊、不适合根治性手术的恶性胸膜间皮瘤患者,54例符合条件并纳入分析。
  • 治疗方案为顺铂75 mg/m2、培美曲塞500 mg/m2及度伐利尤单抗1125 mg静脉给药,每3周一次,化疗最多6周期,度伐利尤单抗最长12个月。
  • 主要终点为按间皮瘤mRECIST评估的6个月无进展生存率,在意向治疗人群中分析。

主要发现

  • 54例患者中31例(57%;95%CI 44-70)在6个月时存活且无进展。
  • 最常见3-4级不良事件为中性粒细胞减少7例(13%)、恶心6例(11%)、贫血4例(7%)。
  • 29例患者共发生60起严重不良事件,其中5起被认为可能与度伐利尤单抗相关。
  • 治疗期间5例患者死亡,均未归因于研究治疗。

关键数值与推荐

  • 6个月无进展生存率为57%(95%CI 44-70),基于54例意向治疗人群。
  • 3-4级中性粒细胞减少发生率为13%(7例),恶心为11%(6例),贫血为7%(4例)。

临床怎么用

  • 该联合方案可作为不可手术恶性胸膜间皮瘤一线治疗的候选方案,但需随机3期试验进一步验证。
  • 治疗期间需重点监测中性粒细胞减少、恶心和贫血等不良事件。

局限性

  • 本研究为单臂2期试验,无随机对照,样本量有限。
  • 研究仅在澳大利亚进行,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is a strong unmet need to improve systemic therapy in mesothelioma. Chemotherapy with cisplatin and pemetrexed improves survival in malignant pleural mesothelioma, and immune checkpoint inhibitors are an emerging treatment in this disease. We aimed to evaluate the activity of durvalumab, an anti-PD-L1 antibody, given during and after first-line chemotherapy with cisplatin and pemetrexed in patients with advanced malignant pleural mesothelioma. METHODS: DREAM was a multicentre, single-arm, open-label, phase 2 trial done in nine hospitals in Australia. Eligible patients were aged 18 years or older and had histologically confirmed malignant pleural mesothelioma considered unsuitable for cancer-directed surgery, an Eastern Cooperative Oncology Group performance status of 0 or 1, and measurable disease as per the modified Response Evaluation Criteria in Solid Tumors version 1.0 (mRECIST) for mesothelioma that was previously untreated with systemic therapy. All histological subtypes were eligible. The first six participants were treated for two cycles in a safety run-in. All participants received cisplatin 75 mg/m2, pemetrexed 500 mg/m2, and durvalumab 1125 mg intravenously on day 1 of a 3-weekly schedule for a maximum of six cycles. Change from cisplatin to carboplatin with an area under the curve of 5 was permitted. Durvalumab was continued for a maximum of 12 months. The primary endpoint was progression-free survival at 6 months, measured according to mRECIST for malignant pleural mesothelioma and analysed in the intention-to-treat population. Safety analyses included all participants who receive at least one dose of any study drug. This study is registered with the Australia New Zealand Clinical Trials Registry, ACTRN12616001170415. FINDINGS: Between Dec 28, 2016, and Sept 27, 2017, 55 participants were enrolled. 54 patients were eligible and were followed up for a median of 28·2 months (IQR 26·5-30·2). 31 (57%; 95% CI 44-70) of 54 patients were alive and progression-free at 6 months. The most common grade 3-4 adverse events were neutropenia (seven [13%] patients), nausea (six [11%]), and anaemia (four [7%]). A total of 60 serious adverse events occurred in 29 participants, five of which were considered possibly related to durvalumab. Five patients died during the study treatment; none of these five deaths were attributed to study treatment. INTERPRETATION: The combination of durvalumab, cisplatin, and pemetrexed has promising activity and an acceptable safety profile that warrants further investigation in a randomised phase 3 trial. FUNDING: AstraZeneca.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Nowak AK, Lesterhuis WJ, Kok PS, et al. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. Lancet Oncol. 2020. PMID: 32888453. doi:10.1016/S1470-2045(20)30462-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。